Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Operating Leases (2019 - 2025)

Guided Therapeutics' Operating Leases history spans 7 years, with the latest figure at $651000.0 for Q4 2025.

  • On a quarterly basis, Operating Leases rose 320.0% to $651000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $651000.0, a 320.0% increase, with the full-year FY2025 number at $651000.0, up 320.0% from a year prior.
  • Operating Leases hit $651000.0 in Q4 2025 for Guided Therapeutics, up from $76000.0 in the prior quarter.
  • Over the last five years, Operating Leases for GTHP hit a ceiling of $651000.0 in Q4 2025 and a floor of $377.0 in Q1 2022.
  • Historically, Operating Leases has averaged $264388.3 across 5 years, with a median of $267000.0 in 2022.
  • Biggest five-year swings in Operating Leases: plummeted 99.9% in 2022 and later skyrocketed 59581.7% in 2023.
  • Tracing GTHP's Operating Leases over 5 years: stood at $325000.0 in 2021, then changed by 0.0% to $325000.0 in 2022, then decreased by 24.31% to $246000.0 in 2023, then tumbled by 36.99% to $155000.0 in 2024, then surged by 320.0% to $651000.0 in 2025.
  • Business Quant data shows Operating Leases for GTHP at $651000.0 in Q4 2025, $76000.0 in Q3 2025, and $130000.0 in Q1 2025.